Navigation Links
Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
Date:5/11/2012

MENLO PARK, Calif., May 11, 2012 /PRNewswire/ -- Depomed, Inc. (NASDAQ: DEPO) today announced that it has received a $1 million milestone payment from Ironwood Pharmaceuticals, Inc. following the development and delivery of a prototype formulation of an Ironwood development candidate meeting pre-specified attributes under its Research Collaboration and License Agreement to license Acuform® technology to Ironwood signed in July 2011. Under the terms of the agreement, Depomed licensed to Ironwood worldwide rights to Depomed's Acuform gastric retentive drug delivery technology for an Ironwood development program directed at gastrointestinal disorders. Under the terms of the agreement, Depomed received an upfront license fee on signing in 2011 and is eligible to receive additional payments pending achievement of certain development and regulatory milestones, as well as royalties on product sales.

About Depomed
Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise™ (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN).  Glumetza® (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and is commercialized by Santarus, Inc. in the United States.  Depomed formulates its products and product candidates with its proven, proprietary Acuform® drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, www.depomed.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995. The statements that are not historical facts contained in this releas
'/>"/>

SOURCE Depomed, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. New 60,000 Square Foot Lease at the Pacific Research Center Signed by Biomed Realty and Depomed
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Fuse Science, Inc. (OTCQB: DROP), ( ... is developing new, patent-pending technologies poised to redefine how consumers ... will hold a business update teleconference and webcast for shareholders ... 2013 at 4:30 PM ET. Fuse Science, ... the call and will be joined by Rubin ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
(Date:5/16/2013)... and ZURICH , May 17, 2013 /PRNewswire/ ... Science, Technology and Research (A*STAR) and Switzerland,s ... volunteer has been dosed in a Phase 1 clinical trial ... bacteriophage Qbeta virus-like particle (VLP) technology. In this first Phase ... vaccine candidate and its potential to protect against H1N1 influenza ...
Breaking Medicine Technology:Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 2A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 3A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 4A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 5A*STAR and Cytos Bring Singapore's First Influenza Vaccine to Clinical Testing 6
... Scientific,Corporation (NYSE: BSX ) today announced ... press announcements at the Cardiovascular Research Foundation,s,(CRF) ... which runs from October 20 to 25 ... be announcing a wide range of safety ...
... the novel,selective relaxant binding agent (SRBA) being developed ... neuromuscular blockade as,compared to neostigmine in the Phase ... Spectrum, faster recovery from profound neuromuscular,blockade compared to ... were presented today at the 2007 annual meeting ...
Cached Medicine Technology:Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007 2Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007 3Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007 4Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007 5Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007 6Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007 7Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 2Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 3Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 4Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia 5
(Date:5/19/2013)... (PRWEB) May 19, 2013 Farming methods ... seed in the ground 10,000 years ago. Most recently, ... farm productivity by using genetically engineered seeds and by ... seeing a backlash to these techniques due to the ... chemicals and a corresponding surge in interest in organic, ...
(Date:5/19/2013)... Angeles (PRWEB) May 19, 2013 Yeast infections ... can appear in sensitive areas of the human body. A ... Yeastrol. This new formula provides a unique method of application ... new spray solution is now provided to men and women ... is naturally absorbed in the body through food and is ...
(Date:5/19/2013)... (PRWEB) May 19, 2013 Beginning Wednesday, May ... Valley Blood Center (RRVBC) will feature “Hot Dog Wednesdays" and ... RRVBC will provide hot dogs and all the fixin's ... slushies each day throughout the summer. “Donors are our lifeline. ... a stable and adequate blood supply. This is a ...
(Date:5/19/2013)... fender benders and serious car accidents are common sights ... to respond appropriately to the situation. According to ... 2010, accidents, including car accidents, are the fifth leading ... automobile accident-related deaths cost over $70 billion ... and passengers receive treatment in an emergency room every ...
(Date:5/18/2013)... COOLA, British Columbia (PRWEB) May 19, 2013 ... to Cooking” (published by iUniverse) , author Janet Hall Svisdahl’s ... delectable world recipes sure to make even the pickiest ... living peacefully, pleasurably and prayerfully,” she explains. , Found ... Spirit” are a wide range of delicious recipes, from fast ...
Breaking Medicine News(10 mins):Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:Auto Accident Infographic Issued by d’Oliveira & Associates on Steps to Take After a Car Crash 2Health News:Janet Hall Svisdahl Announces Release of ‘Cooking with Spirits for the Spirit’ 2
... Two methods that permit scientists to examine ... months release of Cold Spring Harbor Protocols . ... www.cshprotocols.org ), describe how to fluorescently tag cells in ... sophisticated imaging methods, permit scientists to visualize even subtle ...
... Splash with Las Vegas and Tucson Marathon Runners, ... ibuprofen,before an event to prevent inflammation and pain, but ... studies by researchers at,Appalachian State University and Vanderbilt University, ... that taking ibuprofen,before exercise may be unhealthy in the ...
... 3 As momentum continues to,build on the ... in Medicare, the Pharmaceutical Care Management Association,(PCMA) today ... J. Lyle,Bootman, Ph.D., Sc.D., Last year, Dr. ... recommended that all physicians begin using e-prescribing by,2010 ...
... Home Front Needs of Families with Deployed Service Members ... ... Alliance will present $15,000 to the Missouri National Guard -,Missouri Military Family Relief ... and their families., Don Brown, market vice president for the central market ...
... HUNTSVILLE, Ala., Dec. 3 Operon,Biotechnologies, Eurofins MWG ... Genomics network - announced today that they have ... new worldwide leader in the competitive,custom oligonucleotide market. ... of,the art high-throughput production facilities in all major ...
... and CEO retires; Mike Gallagher, President and ... MIAMI, Dec. 3 AvMed Health Plans ... announced plans to retire December 31,2007. As a ... parent company,SantaFe HealthCare, who already has overall leadership ...
Cached Medicine News:Health News:Cold Spring Harbor Protocols features innovative methods for embryology research 2Health News:Marathoners Share Tom Brady and LaDainian Tomlinson Pain Relief Affinity 2Health News:TriWest Contributes $15,000 to Missouri National Guard Fund 2Health News:MWG and Operon Are Joining Forces 2Health News:AvMed Announces Senior Leadership Changes 2
Inquire...
Inquire...
Inquire...
Inquire...
Medicine Products: